BioMarin's stock is in a range-bound consolidation pattern over the past year, with a 1-year price change of +3.18%, significantly underperforming the S&P 500's +19.1% gain. The current price of $58.99 sits at 89% of its 52-week range ($49.26 to $66.28), indicating it is closer to the highs but not at extreme overextension. This positioning suggests a neutral-to-bullish stance, as the stock has recovered from its lows but lacks the momentum to break decisively higher. Short-term momentum is accelerating, with a 1-month price change of +10.63% and a 3-month change of +6.29%, both outpacing the S&P 500's respective -1.25% and +13.56% over the same periods. The 1-month relative strength of +11.88% versus the S&P 500 indicates strong recent outperformance, diverging from the 1-year relative weakness of -15.92%, which could signal a potential trend reversal or mean reversion. The stock's beta of 0.239 is extremely low, meaning it is significantly less volatile than the market, which may appeal to risk-averse investors but also limits upside participation in broad market rallies. Key support lies near the 52-week low of $49.26, while resistance is at the 52-week high of $66.28. A breakout above $66.28 would signal a resumption of the long-term uptrend, while a breakdown below $49.26 could indicate further downside. The low beta suggests that the stock's movements are driven more by company-specific catalysts than market trends.

BioMarin's revenue trajectory shows solid growth, with the most recent quarterly revenue of $874.6 million in Q4 2025 representing a 17.03% year-over-year increase. However, the multi-quarter trend reveals deceleration: revenue grew from $648.8 million in Q1 2024 to $874.6 million in Q4 2025, but the YoY growth rate has slowed from 20.9% in Q2 2025 to 17.0% in Q4 2025. Product revenue of $859.3 million dominates, with royalty and other revenue contributing $15.2 million, indicating core product sales are the primary growth driver. The company swung to a net loss of -$46.6 million in Q4 2025 from a net income of $124.9 million in Q4 2024, driven by a sharp decline in gross margin from 81.8% to 66.3%. Operating margin also turned negative at -5.3% in Q4 2025, compared to +21.6% a year earlier, reflecting higher costs and expenses. The trailing twelve-month net margin stands at 10.8%, but the quarterly volatility suggests profitability is inconsistent. BioMarin maintains a strong balance sheet with a current ratio of 5.21 and a debt-to-equity ratio of only 0.106, indicating minimal leverage. Free cash flow for the trailing twelve months is $724.96 million, providing ample liquidity for internal growth and pipeline investment. Return on equity is 5.73%, which is modest but positive, and the company has no dividend payout, reinvesting all earnings into the business.